UCSF UC San Francisco Previously Published Works

Title

Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis

Permalink https://escholarship.org/uc/item/4rj1j0sg

Journal Journal of Pediatric Gastroenterology and Nutrition, 78(5)

ISSN

0277-2116

Authors

Patel, Perseus V Zhang, Amy Bhasuran, Balu <u>et al.</u>

Publication Date

2024-05-01

DOI

10.1002/jpn3.12169

Peer reviewed

Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis

Perseus V. Patel, MD^{1,2}; Amy Zhang, MPH³; Balu Bhasuran, PhD⁴; Vignesh G. Ravindranath, BS⁴; Melvin B. Heyman, MD¹; Sofia G. Verstraete, MD¹; Atul J. Butte, MD, PhD^{1,5}; Michael J. Rosen, MD, MSCI²; Vivek A. Rudrapatna, MD, PhD^{4,5}; ImproveCareNow Pediatric IBD Learning Health System

¹Department of Pediatrics, University of California San Francisco, San Francisco, CA ²Division of Pediatric Gastroenterology, Stanford University School of Medicine, Palo Alto, CA ³Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, CA

⁴Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA

⁵Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA

Author Contributions

Perseus Patel (corresponding author): patelpe@stanford.edu

- Study conception and design.
- Acquisition, analysis, and interpretation of the data.
- Primary author of the manuscript.

Amy Zhang:

- Substantial contribution to analysis and interpretation of data.
- Critical revision of the manuscript for important intellectual content.

Balu Bhasuran:

- Substantial contribution to analysis and interpretation of data.
- Critical revision of the manuscript for important intellectual content. Vignesh Ravindranath:
 - Substantial contribution to analysis and interpretation of data.
- Critical revision of the manuscript for important intellectual content. Melvin B. Heyman:
 - Significant contributions to project design and analysis plan.
 - Critical revision of the manuscript for important intellectual content.

Sofia G. Verstraete:

• Significant contributions to project design and analysis plan.

• Critical revision of the manuscript for important intellectual content.

Michael J. Rosen:

- Significant contributions to study design.
- Substantial contribution to analysis and interpretation of data.
- Critical revision of the manuscript for important intellectual content.

Atul J. Butte:

• Critical revision of the manuscript for important intellectual content. Vivek A. Rudrapatna:

- Essential in study conception and design.
- Substantial contribution to analysis and interpretation of data.
- Critical revision of the manuscript for important intellectual content.

Postal Address:

750 Welch Road, Suite 116 Palo Alto, CA 94304

Funding Sources: This work is supported in part by NIH T32 DK007762 (PVP). Research

reported in this publication was supported by the National Library of Medicine of the National Institutes of Health under Award Number K99LM014099 (to VAR), and the National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number TL1TR001883. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding provided by the UCSF Division of Gastroenterology, Bakar Computational Health Sciences Institute, and the Stanford Medicine Children's Health Center for IBD and Celiac Disease.

Word Count: 2984

Number of Figures: 1

Number of Tables: 3

Key Words: <u>childrenpediatrics</u>, inflammatory bowel disease, <u>ulcerative colitis</u>, biologic therapy, clinical data science, <u>comparative effectiveness</u>, <u>real-world evidence</u>

Conflicts of Interest:

VAR receives grant funding from Alnylam, Genentech, Merck, Takeda, Janssen, Blueprint Medicines, Stryker, and Mitsubishi Tanabe.

VAR receives grant support from the following for-profit entities: Janssen Inc, Alnylam Inc, Merck Inc, and Genentech Inc.

AJB is a co-founder and consultant to Personalis and NuMedii; consultant to Mango Tree Corporation, and in the recent past, Samsung, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook), Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, Regeneron, Sanofi, Pfizer, Royalty Pharma, Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences, Editas Medicine, Nuna Health, Assay Depot, and Vet24seven, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. Atul Butte receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. Atul Butte's research has been funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor's Office of Planning and Research, California Institute for Regenerative Medicine, L'Oreal, and Progenity.

MJR has served on advisory boards for Pfizer, and Fresenius Kabi, and as a consultant for Federation Bio.

1 Abstract

2 Background

3 Vedolizumab (VDZ) and ustekinumab (UST) are second-line treatments in pediatric 4 patients with ulcerative colitis (UC) refractory to anti-tumor necrosis factor (anti-TNF) therapy. 5 Pediatric studies comparing the effectiveness of these medications are lacking. 6 Aim 7 Using a registry from ImproveCareNow (ICN), a global research network in pediatric 8 inflammatory bowel disease, we compared the effectiveness of UST and VDZ in anti-TNF 9 refractory UC. 10 **Methods** 11 We performed a propensity-score weighted regression analysis to compare corticosteroid 12 free clinical remission (CFCR) at 6 months from starting second-line therapy. Sensitivity 13 analyses tested the robustness of our findings to different ways of handling missing outcome 14 data. Secondary analyses evaluated alternative proxies of response and infection risk. 15 **Results** 16 Our cohort included 262 patients on VDZ and 74 patients on UST. At baseline, the two 17 groups differed on their mean pediatric UC activity index (PUCAI) (p=0.03) but were otherwise 18 similar. At month 6, 28.3% of patients on VDZ and 25.8% of those on UST achieved CFCR 19 (p=0.76). Our primary model showed no difference in CFCR [odds ratio 0.81; 95% CI: 0.41-20 1.59] (p=0.54). The time to biologic discontinuation was similar in both groups [hazard ratio 21 1.26; 95% CI: 0.76-2.08] (p=0.36), with the reference group being VDZ, and we found no 22 differences in clinical response, growth parameters, hospitalizations, surgeries, infections, or 23 malignancy risk. Sensitivity analyses supported these findings of similar effectiveness.

$\gamma 4$	α α	•
24 (Onc	lusions
27 1	Conci	lusions

25	UST and VDZ are similarly effective for treating anti-TNF refractory UC in pediatric
26	patients. Providers should consider safety, tolerability, cost, and comorbidities when deciding
27	between these therapies.
28	What is Known?
29	• Anti-tumor necrosis factor (anti-TNF) medications are first line therapy for pediatric
30	patients with moderate to severe ulcerative colitis.
31	• A significant proportion of patients will be primary non-responders or experience loss of
32	response to anti-TNFs.
33	• Vedolizumab (VDZ) and ustekinumab (UST) are common second-line treatments for
34	these patients.
35	What is New?
36	• UST and VDZ have similar effectiveness in this cohort, with equivalent rates of
37	corticosteroid-free clinical remission, clinical response, hospitalizations, surgeries, and
38	biologic persistence.
39	• These results are consistent across multiple methods of correcting for missing data in the
40	ImproveCareNow (ICN) Registry.
41	Introduction
42	In contrast to its adult-onset disease, pediatric patients with ulcerative colitis (pUC)
43	commonly present with extensive disease associated with higher rates of hospitalization,
44	corticosteroid failure, colorectal cancer risk, and up to 20% colectomy rate within 5-years of

45 diagnosis^(1, 3-6). Anti-tumor necrosis factor (anti-TNF) medications are first-line treatments for

46 moderate to severe pUC, with adalimumab and infliximab being the only Food and Drug 47 Administration (FDA) approved biologics for children ^(6,7). However, up to 30% of patients do 48 not respond to anti-TNF induction doses, and as many as 45% of responders subsequently lose 49 response within the first year ^(1,7). Patients who are refractory to or intolerant of these drugs 49 usually require treatments with different mechanisms of action, with providers and families 51 having to decide between off-label therapies with less available information about treatment 52 efficacy.

53 Typical options for these patients include vedolizumab (VDZ), an inhibitor of leukocyte 54 trafficking to the intestinal tract⁽⁸⁾, and ustekinumab (UST), an inhibitor of interleukins 12 and 55 $23^{(9)}$. Despite how commonly these medications are needed and applied, an evidence gap exists 56 regarding how to optimally select between these options. At present, no published studies 57 compare efficacy in children. Furthermore, evidence extrapolated from adult studies is 58 inconsistent. A meta-analysis in adult patients with UC showed that both were effective at 59 inducing clinical remission and endoscopic response, while a systematic review in adults with 60 Crohn's Disease favored sustained corticosteroid-free clinical remission (CFCR) with UST^(10, 11). 61 While some comparative effectiveness studies indicate no difference in adults with Crohn's 62 Disease, one favored VDZ for clinical remission, while another suggested UST was superior for 63 $CFCR^{(12-16)}$. It is possible that these conflicting findings may be due in part to differences in 64 outcome measures and methods applied for handling missing data. 65 We sought to address this evidence gap and study the comparative effectiveness of VDZ 66 and UST in anti-TNF-refractory pUC using the ImproveCareNow (ICN) registry. We evaluated 67 multiple measures of effectiveness including CFCR, clinical response, growth and nutritional

68 status, inflammatory bowel disease (IBD)-related hospitalizations, or surgery at 6 months, and

69 time to treatment discontinuation. We also evaluated safety outcomes at 6 months by comparing 70 rates of severe infections and malignancies. Furthermore, we tested the robustness of our results 71 across different potential explanations for missing outcome measures in the context of routine 72 clinical care.

73 Methods

74 Data source

75 We conducted a prospective cohort study of pUC within ICN initiating vedolizumab or 76 ustekinumab therapy as a second line therapy after failure of an anti-TNF drug between October 77 1, 2006, and April 5, 2023. ICN is a pediatric IBD research network initiated in 2006 and has 78 captured data on over 32,000 patients treated across >100 centers. It functions as a learning 79 health system, with a continuously updated database that facilitates patient-centered research to 80 optimize outcomes⁽¹⁷⁾. Institutional review board (IRB) approval is obtained, and participants are 81 enrolled under informed consent at each site. Data are collected at each clinic visit and 82 hospitalization. The captured information includes demographics, disease characteristics, serum 83 and stool tests, medication history, IBD-related surgical history, growth measures, and disease 84 activity scores.

85 Cohort selection criteria

We queried the ICN database to identify pediatric patients (< 21 years old) meeting the
following criteria: 1) a documented, confirmed diagnosis of UC based on the diagnosis at
registration and the most recent visit, 2) anti-TNF exposure based on medications documented
during clinic visits, and 3) VDZ or UST exposure documented in the clinic visit medication list,
without previous exposure documented to either drug (i.e., VDZ or UST as third line therapy
were excluded). Concomitant medications such as immunomodulators or antibiotics were

92 allowed. We excluded patients with a diagnosis of CD or inflammatory bowel disease 93 unclassified, history of colectomy, and those who were started on VDZ or UST prior to anti-TNF 94 therapy. These queries identified 381 pUC who failed anti-TNFs and were subsequently treated 95 with UST or VDZ. Anti-TNF failure was defined as anti-TNF use and cessation prior to 96 treatment with VDZ or UST. Patients must have exhibited active disease at the visit prior to the 97 first recorded visit on VDZ or UST, defined as a Pediatric Ulcerative Colitis Activity Index 98 (PUCAI) >10⁽¹⁸⁾ or a physician global assessment (PGA) > 1 (if PUCAI not available), or current 99 corticosteroid use, or abnormal inflammatory markers (C-reactive protein \geq 5mg/L). These 100 markers were selected in alignment with guideline-based early treat-to-target goals⁽¹⁹⁾.

101 *Baseline and outcome periods*

102 The timing of clinic visits and data capture in real-world settings commonly differs from 103 those in controlled studies due to a variety of factors, including provider practice patterns, 104 patients' state of illness or health, and social determinants of health impacting the ability to 105 follow-up⁽²⁰⁾. ICN is a learning collaborative that disseminates best practice recommendations⁽²¹⁾, 106 but there are no formal guidelines on monitoring pediatric patients on UST or VDZ. Therefore, 107 patients in our study were monitored based on individual center protocols and provider 108 recommendations. To emulate a hypothetical trial with planned study visits and to minimize the 109 effects of missing data and selection bias, we performed an exploratory data analysis and 110 retrospectively defined time windows corresponding to the baseline and outcome periods. 111 We defined the baseline as the clinic visit before the first documentation of VDZ or UST 112 use for a patient. Although this corresponds to a date prior to the true date of treatment induction 113 (which is not well-captured across the dataset), we chose this definition because it most 114 accurately reflects the patient's clinical status at the time of deciding between second-line

therapies. To address missing baseline data, we used the *sklearn* implementation of Iterative
Imputation , a method that iteratively imputes each missing variable as a function of all other
variables until convergence is achieved ⁽²²⁾.

118 Our outcome period was month 6 ± 2 months after baseline. This minimized missing 119 data, accounted for differences in medication time to onset, and was in-line with previous IBD 120 comparative effectiveness literature ⁽¹⁴⁾. For those who had multiple clinic visits during the 121 outcome period, we selected data from the visit closest to day 183 relative to baseline.

122 *Study Endpoints*

Our primary endpoint was corticosteroid-free clinical remission (CFCR), a composite binary variable defined as a PUCAI <10 or PGA=1, in addition to the absence of all of the following during the outcome period: therapy discontinuation, IBD-related hospitalization or surgery (pre-defined variables in ICN), or continued corticosteroid use (including budesonide) at the outcome visit. ^(1, 23) PGA was used in visits where a complete PUCAI was not documented. As fecal calprotectin was collected in only 10% of visits during the outcome window, we did not incorporate it into our primary endpoint.

Our secondary endpoints included corticosteroid-free clinical response, IBD-related hospital admissions and surgeries, growth, nutrition, infections, malignancies, and biologic durability. Clinical response was a binary outcome that included patients in remission, and as per the STRIDE-II guidelines included those with a decrease in PUCAI $\geq 20^{(19)}$, or a PGA indicating mild or quiescent disease. Growth and nutritional status were evaluated based upon pre-defined ordinal variables in the ICN database. Serious infection, a pre-defined ICN variable, encompassed any infection that required hospitalization or intravenous treatment. As an

137	alternative measure of effectiveness, we evaluated time to treatment discontinuation. This was
138	determined through the current medications documented at each visit after the baseline visit.
139	Statistical Methods
140	Primary Outcomes
141	We used a stabilized inverse probability of treatment weighted (IPTW) logistic regression
142	model to compare the likelihood of CFCR between treatment groups. Baseline differences were
143	assessed using traditional significance testing (Fisher's exact test, Student's t-test, Mann-
144	Whitney U as appropriate) as well as standardized mean differences (SMDs) given the disparity
145	in cohort sizes. As per established measures, w <u>W</u> e used >0.2, >0.5, and >0.8 cutoffs for SMD to
146	represent small, moderate, and large differences ^(24, 25) . For this stabilized IPTW model, the
147	numerator for the weights was the probability of treatment selection irrespective of the
148	covariates, and the denominator represented the probability of treatment selection based on all
149	baseline variables in Table 1 ⁽²⁶⁾ .
150	We performed a complete case analysis as our primary approach to analyzing the data.
151	This approach assumes that the patients with captured outcomes are representative of the study
152	population. We considered this assumption reasonable with the understanding that many missing
153	outcome measurements at month 6 may reflect idiosyncratic practice styles around the timing of
154	follow-up, patient preferences, and other factors that are independent of a patient's clinical
155	status. However, given the possibility of alternative explanations for missing data in real-world
156	contexts, we performed sensitivity analyses to test the robustness of our primary findings, as
157	detailed in our supplemental methods.
150	

Secondary Outcomes

159 We used a logistic regression analysis adjusted for baseline differences in our treatment 160 cohorts to compare the odds of patients achieving a clinical response at month-6. We also used 161 Fisher's exact testing to compare growth status, nutritional status, prevalence of hospitalizations, 162 surgeries, malignancies, and serious infections between the treatment groups from baseline until 163 the month-6 follow-up visit. 164 To compare the rates of medication discontinuation for up to 1 year of follow-up, we 165 conducted a multivariate analysis using a Cox regression that controlled for baseline differences 166 noted in Table 1. Follow-up was censored at the date of medication change. Patients who had 167 been followed for < 1 year after starting their second-line therapy were censored at the time of 168 their last visit. 169 Ethics 170 The Human Research Protection Program IRB at the University of California San 171 Francisco (IRB#21-34392) approved this study. At each participating center, patients were 172 consented for their data to be shared with ICN and used for research. 173 Results 174 Data Capture 175 At baseline, disease characteristics such as Paris Classification, extra-intestinal 176 manifestations, growth status, and current medications were captured in >95% of patients. Serum 177 lab values were documented in 80-94% of patients and were similar across the two groups at 178 baseline (Supplemental Table 1). 179 The primary outcome of CFCR was captured in 89% of the cohort (299/336). This degree 180 of outcome capture was similar in both the VDZ (88.9%; 233/262) and UST (89.1%; 66/74) sub-181 cohorts (p=0.95).

182 Baseline Characteristics

183 Our study included 336 patients started on either VDZ (262) or UST (74). Patients were 184 seen at 76 ICN centers, all in the United States. The treatment groups differed slightly on PUCAI 185 scores [VDZ 26.8 (IQR: 10-40) vs UST 20.0 (IQR: 5-30); SMD=0.29] and concomitant 186 immunomodulator use [VDZ 21.4% vs UST 12.2%; SMD=0.23] (Supplemental Table 1, 187 Supplemental Figure 1). Otherwise, the groups were well-balanced with no differences were 188 found in gender, age at diagnosis, age at initiating second-line biologic therapy, corticosteroid 189 use, baseline serum labs, growth trajectories, nutritional status, PGA, or extra-intestinal 190 manifestations (Supplemental Table 1). Descriptive characteristics of the cohort remained stable 191 after imputation (Table 1), and stabilized IPTW ensured appropriate balance across all baseline 192 variables during modeling. 193 Primary Endpoint 194 We performed a complete case analysis as our primary method for analyzing the data. In 195 the study cohort, the proportions of CFCR were similar across treatment arms: 28.3% (VDZ) 196 versus 25.8% (UST). An unadjusted odds ratio (OR) showed no difference between the two 197 medications; OR=0.88 [95% confidence interval (CI) 0.47-1.63] (p=0.68). In the propensity-198 weighted model, the differences remained non-significant; OR = 0.81 [0.41-1.59] (p=0.54, Table 2), 199 suggesting similar effectiveness. 200 Sensitivity Analyses 201 We performed two sensitivity analyses to test whether our findings would remain stable 202 under alternative methods for handling missing outcomes, an issue that affected 11% of our

203 cohort. These included: 1) non-responder imputation (patients missing outcomes were assumed

to be non-responders) to model scenarios where patients who are too ill to follow-up, and 2)

205	responder imputation (patients missing outcomes were assumed to be responders) to model
206	scenarios where patients who are well are less inclined to follow-up. These analyses supported
207	the conclusion of similar effectiveness between UST and VDZ (Table 2).
208	Secondary Endpoints
209	Clinical response was achieved in 39.7% of patients on VDZ and 30% of patients on UST
210	(Fisher's exact test, p=0.20) (Table 3). In a multivariate regression model that controlled for
211	baseline differences in PUCAI and immunomodulator use, the odds of achieving clinical
212	response remained non-significant (OR: 0.65 [0.36-1.15], p=0.14). The only predictor of
213	achieving clinical response (OR: 0.36 [0.21-0.63], p<0.001) or CFCR (OR: 0.33 [0.18-0.62],
214	p<0.001) at month-6 was not needing corticosteroids at baseline.
215	At their outcome visit, 82.7% of patients on VDZ and 84.2% of patients on UST had a
216	satisfactory nutritional status (p=0.83) while 89.2% of patients on VDZ and 94.0% of patients on
217	UST had a satisfactory growth status (p=0.24) (Table 3). The proportion of patients hospitalized
218	were similar between the treatment arms—12.2% (VDZ) versus 10.8% (UST) (p=0.74).
219	Surgeries and infections were rare (<10 patients), and no malignancies were reported in either
220	group (Table 3).
221	By 1-year from the start of their second-line biologic, 32% of patients who were started
222	on VDZ and 40% of patients who were started on UST discontinued the medication. We
223	performed a Cox regression that controlled for baseline covariates and found the hazard of
224	medication discontinuation among those on UST was 1.26 times that of patients on VDZ (95%
225	CI: 0.76-2.08, p=0.36) (Figure 1).
226	Discussion

227	This is the first comparative effectiveness study of second-line therapies in pediatric
228	patients with UC who failed anti-TNF therapy. Studies on comparative effectiveness in adult
229	populations between these two drugs demonstrated varied results ⁽¹¹⁻¹⁶⁾ . Using the ICN registry,
230	we found that VDZ and UST are similarly effective at inducing CFCR at month-6. This finding
231	of similar efficacy remained robust under a range of sensitivity analyses and secondary
232	effectiveness and safety endpoints. While there are inherent limitations in observational-
233	work <u>research using observational data</u> , our study helps alleviate the uncertainty that accompanies
234	extrapolation from adult cohorts and serves as hypothesis-generating work for future prospective
235	studies that help define treatment positioning in pUC.
236	We found a 25-30% remission rate and 30-40% response rate for the two drugs. Clinical
237	trial data for multiple biologic therapies show lower remission rates in TNF-exposed versus
238	TNF-naïve patients (27-30). Patients who do not respond to anti-TNF are approximately 25% less
239	likely to respond to second-line biologics, and both UST and VDZ are more effective in anti-
240	TNF naïve patients with $UC^{(10, 31)}$. In a post-hoc analysis of the GEMINI trial, 36.1 % of anti-
241	TNF refractory UC patients achieved remission with VDZ (28). A prospective trial in TNF-
242	refractory pUC showed that 24% of the pediatric patients achieved CFCR at 6-months ⁽³²⁾ .
243	We strove to address limitations in existing real-world studies through the analysis of
244	multiple endpoints, use of propensity scores to address selection bias, and selective measures to
245	address reasons for incomplete data. We utilized both inpatient and outpatient elements in the
246	ICN database, including hospitalizations and surgeries, to define clinical remission. Propensity
247	scoring minimized selection bias while maintaining cohort size and minimizing loss of power ⁽³³⁾ .
248	Our results were consistent across multiple models that represented underlying reasons for

missingness in real-world settings. Lastly, we compared alternative proxies of effectiveness,
which also showed equivalency. The slightly higher persistence of VDZ was not statistically
significant and may be due to its longer time-to-onset or due to lack of other FDA-approved
options. Overall, the consistent findings noted throughout our analyses support the hypothesis of
similar effectiveness in anti-TNF refractory pUC.

254 The potential for residual bias exists in observational workall retrospective research. Few 255 pediatric resources are as large as ICN, but the nature of collecting data concurrent with clinical 256 care creates heterogeneity in data collection. This is commonly due to practice variation among 257 providers and heterogeneity in patients' disease states, with diagnostics being ordered based on 258 health status rather than a pre-set schedule as seen in prospective trials. Therefore, patients may 259 not have had a clinic visit during our outcome window, or information from the visit may not 260 have been appropriately documented. Additionally, as labs collected outside the treating 261 institution are not routinely uploaded into the database, we were unable to include biomarkers or 262 therapeutic drug monitoring into our study. The database does not accurately capture medication 263 induction dates, dosing changes or reasons for discontinuation.

264 An additional limitation of our study is the sample size discrepancy between the two 265 groups, which may reduce precision. This is likely because VDZ was approved earlier than UST 266 for IBD, and parents may prefer VDZ given its lower systemic immune suppression^(34, 35). In a 267 recent ICN study, sequential anti-TNF therapy with infliximab then adalimumab or vice-versa 268 were the most common patterns of biologic use in pediatric IBD, with significantly lower rates of 269 drugs with alternative mechanisms of action⁽³⁶⁾. This likely speaks to the limited FDA-approved 270 therapies, and possible provider and/or patient comfort with using off-label biologics. As ICN 271 grows, these imbalances may decrease over time.

272 Future work should focus on improving data quality so that real-world evidence studies 273 using real-world data can more closely mimic emulate randomized clinical trials. Potential 274 drivers of missing data in ICN include the variation in follow-up timing, differences in clinic 275 note templates across centers, and the large number of data points to collect. To combat 276 variability in free-text information and the burden of information extraction, natural language 277 processing techniques have shown promise in extracting extraintestinal manifestations of IBD 278 from clinical notes, and Mayo scores from colonoscopy reports^(37, 38). Future endeavors to 279 automate the extraction of IBD-relevant variables from the electronic health record, including 280 patient symptoms, radiographic, endoscopic, and histologic measures, can improve the 281 completeness of our registries and enhance the quality of downstream research. 282 In conclusion, we found that VDZ and UST have similar rates of CFCR in anti-TNF 283 refractory pUC. The replicability of our results supports that large disparities do not exist, but 284 physicians should apply these findings cautiously given the inherent limitations of observational 285 work. Larger randomized clinical trials are needed to validate these findings. As treat-to-target 286 goals evolve, the inclusion of biomarkers, endoscopic, and imaging data will improve future 287 comparisons between medications. However, this initial hypothesis-generating study proves that 288 ICN has the potential to provide insight into clinically relevant questions that would otherwise 289 require costly, time-consuming trials. Given the current data, we recommend that clinicians 290 adopt a patient-specific approach to this decision that weights safety, tolerability, cost, route of 291 administration, patient preference, and alternative indications in addition to treatment 292 effectiveness.

- 293 Acknowledgements: We thank ICN for providing access to their database, Kelly Olano for her
- support with data extraction, NIH T32 DK007762 and Stanford Medicine Children's Health
- 295 Center for IBD and Celiac Disease for PVP's support, and the UCSF Information Commons
- team for their computing support.

References

- Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. *Journal of Pediatric Gastroenterology and Nutrition* 2018; 67:257–291. https://doi.org/10.1097/ MPG.000000000002035
- Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. *Journal of Pediatric Gastroenterology and Nutrition* 2018; 67:292– 310. https://doi.org/10.1097/MPG.00000000002036
- 3. Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. *Gut* 2008; 57:331–338. https://doi.org/10.1136/gut.2007.136481
- Levine A, de Bie CI, Turner D, et al. Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry. *Inflamm Bowel Dis* 2013; 19:370–377. https://doi.org/10.1002/ibd.23013
- 5. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. *Am J Gastroenterol* 2009; 104:2080–2088. https://doi.org/10.1038/ajg.2009.177
- 6. Croft NM, Faubion WA, Kugathasan S, et al. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. *Lancet Gastroenterol Hepatol* 2021; 6:616–627. https://doi.org/10.1016/S2468-1253(21)00142-4
- Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. *Clin Gastroenterol Hepatol* 2012; 10:391-399.e1. https://doi.org/10.1016/j.cgh.2011.11.026
- 8. Neurath MF. Current and emerging therapeutic targets for IBD. *Nat Rev Gastroenterol Hepatol* 2017; 14:269–278. https://doi.org/10.1038/nrgastro.2016.208
- Guillo L, D'Amico F, Danese S, et al. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. *Journal of Crohn's and Colitis* 2021; 15:1236–1243. https://doi.org/10.1093/ecco-jcc/jjaa260
- Burr NE, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. *Gut* 2022; 71:1976–1987. https://doi.org/10.1136/gutjnl-2021-326390

- Parrot L, Dong C, Carbonnel F, et al. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor. *Alimentary Pharmacology & Therapeutics* 2022; 55:380–388. https://doi.org/10.1111/apt.16714
- 12. Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. *Aliment Pharmacol Ther* 2020; 51:948–957. https://doi.org/10.1111/apt.15706
- Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease. *Alimentary Pharmacology & Therapeutics* 2020; 52:1341–1352. https://doi.org/10.1111/apt.16057
- 14. Biemans VBC, van der Woude CJ, Dijkstra G, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. *Aliment Pharmacol Ther* 2020; 52:123–134. https://doi.org/10.1111/apt.15745
- 15. Kappelman MD, Adimadhyam S, Hou L, et al. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. *Official journal of the American College of Gastroenterology* | *ACG* 2023; 118:674. https://doi.org/10.14309/ajg.00000000002068
- Onali S, Pugliese D, Caprioli FA, et al. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. Official journal of the American College of Gastroenterology | ACG 2022; 117:1279. https://doi.org/10.14309/ajg.00000000001773
- 17. Anon. ImproveCareNow Purpose & Success. ImproveCareNow. https://www.improvecarenow.org/purpose-success. Accessed July 2, 2022
- Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. *Gastroenterology* 2007; 133:423–432. https://doi.org/10.1053/j.gastro.2007.05.029
- Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. *Gastroenterology* 2021; 160:1570–1583. https://doi.org/10.1053/j.gastro.2020.12.031
- 20. Rudrapatna VA, Cheng Y-W, Feuille C, et al. Creation of a ustekinumab external control arm for Crohn's disease using electronic health records data: a pilot study. 2021:2021.11.12.21266064.
- 21. ImproveCareNow[™]. Program Details. ImproveCareNow. https://www.improvecarenow.org/program-details. Accessed October 16, 2023

- 22. Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software* 2011; 45:1–67. https://doi.org/10.18637/jss.v045.i03
- 23. Yanagi T, Ushijima K, Koga H, et al. Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan. *Intest Res* 2019; 17:476–485. https://doi.org/10.5217/ir.2019.00027
- 24. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Academic Press; 2013.
- 25. Andrade C. Mean Difference, Standardized Mean Difference (SMD), and Their Use in Meta-Analysis: As Simple as It Gets. *J Clin Psychiatry* 2020; 81:20f13681. https://doi.org/10.4088/JCP.20f13681
- 26. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med* 2015; 34:3661–3679. https://doi.org/10.1002/sim.6607
- 27. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. *New England Journal of Medicine* 2016; 375:1946–1960. https://doi.org/10.1056/NEJMoa1602773
- Feagan BG, Rubin DT, Danese S, et al. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. *Clin Gastroenterol Hepatol* 2017; 15:229-239.e5. https://doi.org/10.1016/j.cgh.2016.08.044
- 29. Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. *Inflamm Bowel Dis* 2017; 23:97–106. https://doi.org/10.1097/MIB.00000000000979
- 30. Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. *Lancet* 2014; 384:309–318. https://doi.org/10.1016/S0140-6736(14)60661-9
- Singh S, George J, Boland BS, et al. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. *J Crohns Colitis* 2018; 12:635–643. https://doi.org/10.1093/ecco-jcc/jjy004
- 32. Dhaliwal J, McKay HE, Deslandres C, et al. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study. *Aliment Pharmacol Ther* 2021; 53:1300–1308. https://doi.org/10.1111/apt.16388
- 33. Xu S, Ross C, Raebel MA, et al. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. *Value Health* 2010; 13:273–277. https://doi.org/10.1111/j.1524-4733.2009.00671.x

- Cohen RD, Bhayat F, Blake A, et al. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. *J Crohns Colitis* 2020; 14:192–204. https://doi.org/10.1093/ecco-jcc/jjz137
- 35. Hazlewood GS, Pokharel G, Deardon R, et al. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. *PLoS One* 2020; 15:e0227635. https://doi.org/10.1371/journal.pone.0227635
- Kaplan JL, Liu C, King EC, et al. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort. *J Pediatr Gastroenterol Nutr* 2023; 76:566–575. https://doi.org/10.1097/MPG.00000000003734
- Cai T, Lin T-C, Bond A, et al. The Association Between Arthralgia and Vedolizumab Using Natural Language Processing. *Inflamm Bowel Dis* 2018; 24:2242–2246. https://doi.org/10.1093/ibd/izy127
- Silverman AL, Bhasuran B, Mosenia A, et al. Accurate, Robust, and Scalable Machine Abstraction of Mayo Endoscopic Subscores from Colonoscopy Reports. 2022:2022.06.19.22276606.
- Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. *J Crohns Colitis* 2020; 14:694–709. https://doi.org/10.1093/eccojcc/jjz195
- 40. Anyane-Yeboa A, Quezada S, Rubin DT, et al. The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology* 2022. https://doi.org/10.1016/j.cgh.2022.03.011
- Bernstein CN, Walld R, Marrie RA. Social Determinants of Outcomes in Inflammatory Bowel Disease. *Am J Gastroenterol* 2020; 115:2036–2046. https://doi.org/10.14309/ajg.00000000000794
- 42. Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus Adalimumab for Moderateto-Severe Ulcerative Colitis. *New England Journal of Medicine* 2019; 381:1215–1226. https://doi.org/10.1056/NEJMoa1905725
- Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *New England Journal of Medicine* 2017; 376:1723–1736. https://doi.org/10.1056/NEJMoa1606910

Supplemental Methods

Sensitivity Analyses:

We designed sensitivity analyses to address potential biases related to missing outcome data. To test the robustness of our findings to our choice of the complete case analysis method, we designed two sensitivity analyses, each corresponding to an alternative explanation for missing outcome data in real-world settings. (1) Non-responder imputation. This is a method commonly used in the analysis of IBD clinical trials ^(42, 43) and accounts for patients who may have been too ill to present to clinic. (2) Responder imputation. This corresponds to a situation where responders and symptomatically quiescent patients are less inclined to follow-up due to lack of clinical necessity.

	Vedolizumab	Ustekinumab	p-value	\mathbf{SMD}^{Ω}
N	262	74	-	-
Female	128 (48.9%)	33 (44.6%)	0.60	0.08
Age at diagnosis (years),	13.5 [10.3-15.6]	13.1 [11.6-16.5]	0.25	0.15
median [IQR*]				
Age at baseline visit	16.2 [13.5-18.3]	16.6 [14.0-18.5]	0.38	0.12
(years), median [IQR]				
Disease duration at baseline	2.0 [1.0-3.7]	1.5 [0.8-4.1]	0.74	0.04
visit (years), median [IQR]				
Paris Classification				
Extent (pancolitis)	186 (71.0%)	53 (71.6%)	0.41	0.06
Severity (S1)	124 (47.3%)	32 (43.2%)	0.24	0.18
Immunomodulators	56 (21.4%)	9 (12.2%)	0.13	0.23
Corticosteroids	112 (42.7%)	25 (33.8%)	0.20	0.17
Labs, median [IQR]				
Hematocrit (%)	37.9 [34.6-40.9]	37.3 [33.4-40.6]	0.66	0.06
C-reactive protein (mg/L)	1.8 [0.5-5.5]	2.2 [0.5-6.2]	0.79	0.03
Sedimentation rate (mm/h)	17.0 [9.0-29.0]	16.0 [9.0-26.0]	0.58	0.07
Albumin (g/dL)	4.0 [3.7-4.3]	4.1 [3.7-4.4]	0.78	0.04
[#] Growth (satisfactory)	225 (85.6%)	65 (87.8%)	0.32	0.13
*Nutrition (satisfactory)	192 (73.3%)	58 (78.4%)	0.48	0.14
^PUCAI, median [IQR]	26.8 [10-40]	20 [5-30]	0.03	0.29
°Extra-intestinal	< 10	<10	0.76	0.06
manifestations				

Table 1: Baseline characteristics after imputation

 $^{\Omega}$ Standardized mean difference.

*IQR: interquartile range.

*Pre-defined ImproveCareNow variables.

^PUCAI: Pediatric Ulcerative Colitis Activity Index.

^oExtra-intestinal manifestations include arthritis, fevers, pyoderma gangrenosum, erythema nodosum and uveitis.

Analysis Method	Odds Ratio	95% confidence	p-value
		interval	
Unweighted cohort	•	•	•
Complete case analysis	0.78	0.42-1.48	0.45
Impute missing as non-responder	0.80	0.43-1.48	0.48
Impute missing as responder	0.80	0.46-1.39	0.43
Propensity-score weighted cohort			
Complete case analysis	0.81	0.41-1.59	0.54
Impute missing as non-responder	0.94	0.50-1.78	0.85
Impute missing as responder	0.90	0.51-1.60	0.73

 Table 2: Results for corticosteroid-free clinical remission

Outcome Measure	Vedolizumab	Ustekinumab	p-value
Clinical Response	39.7% (n=232)	30.3% (n=66)	0.20
IBD-related hospitalizations	12.2% (n=262)	<10 (n=74)	0.74
IBD-related surgeries	<10 (n=262)	<10 (n=74)	0.43
Nutritional Status (satisfactory)	82.7% (n=168)	84.2% (n=38)	0.83
Growth status (satisfactory)	89.2% (n=251)	94.0% (n=67)	0.24
Infections	<10 (n=167)	<10 (n=38)	0.89
Malignancies	0% (n=232)	0% (n=66)	-

Table 3: The secondary endpoints of clinical remission, nutritional status, and growth status are assessed during the outcome time window of month-6 + 2 months. The secondary endpoints of hospitalizations, surgeries, malignancies, and infections were evaluated from baseline until the month-6 follow-up visit.




Figure 1: Time-to-event analyses for biologic durability

Figure 1: Cox estimate for time to discontinuation of the second-line biologic with a hazard ratio that accounts for control of all baseline covariates.

Supplemental Table 1: Baseline Characteristics prior to imputation

 $^{\Omega}$ Standardized mean difference.

*IQR: interquartile range.


[#]*Pre-defined ImproveCareNow variables.*

^PUCAI: Pediatric Ulcerative Colitis Activity Index.

^oExtra-intestinal manifestations include arthritis, fevers, pyoderma gangrenosum, erythema nodosum and uveitis.

	Vedolizumab	Ustekinumab	p-value	\mathbf{SMD}^{Ω}
N	262	74	-	-
Female	128 (48.9%) (n=262)	33 (44.6%) (n=74)	0.60	0.09
Age at diagnosis (years),	13.9 [9.9-15.6]	13.3 [11.3-16.8]	0.20	0.17
median [IQR*]	(n=243)	(n=67)		
Age at baseline visit	16.4 [13.3-18.4]	16.9 [14.2-18.5]	0.33	0.13
(years), median [IQR]	(n=262)	(n=74)		
Disease duration at baseline	1.9 [1.0-3.7] (n=243)	1.5 [0.8-4.6] (n=67)	0.91	0.01
visit (years), median [IQR]				
Paris Classification				
Extent (pancolitis)	184 (70.2%) (n=253)	50 (67.6%) (n=70)	0.75	0.07
Severity (S1)	124 (47.3%) (n=253)	31 (41.9%) (n=70)	0.38	0.18
Immunomodulators	56 (21.7%) (n=258)	9 (12.5%) (n=72)	0.11	0.23
Corticosteroids	112 (42.7%) (n=258)	25 (33.8%) (n=70)	0.22	0.17
Labs, median [IQR]				
Hematocrit (%)	38.0 [34.5-41]	37.5 [33.4-40.7]	0.73	0.05
	(n=247)	(n=69)		
C-reactive protein (mg/L)	1.1 [0.3-4.7] (n=219)	1.0 [0.3-4.1] (n=59)	0.85	0.03
Sedimentation rate (mm/h)	16.0 [8.0-29.0]	14.5 [8.0-27.0]	0.57	0.08
	(n=238)	(n=68)		
Albumin (g/dL)	4.1 [3.7-4.3] (n=246)	4.1 [3.7-4.4] (n=69)	0.67	0.06
[#] Growth (satisfactory)	221 (84.4%) (n=249)	63 (85.1%) (n=67)	0.44	0.12
*Nutrition (satisfactory)	192 (73.3%) (n=258)	58 (78.4%) (n=72)	0.84	0.13
^PUCAI, median [IQR]	25 [10-40] (n=246)	20 [5-30] (n=69)	0.03	0.30
°Extra-intestinal	<10 (n=254)	<10 (n=72)	0.76	0.04
manifestations				

Supplemental Figure 1



Supplemental Figure 1: Box and whisker plot showing the changes in pediatric ulcerative colitis activity index (PUCAI) scores across time for each treatment group. The box spans the interquartile range (IQR), while the whiskers include values that differ from the upper and lower box bounds by less than 1.5*IQR.